RecruitingNCT06943404
BXCL501 for acute stress symptoms in emergency patients
About this title
Read the official source — NCT06943404Medication studyAges 18–65United StatesPTSD
Understand this study
Who could participate?
Listed age limits: 18 years to 65 years.
- Listed locations
- Jacksonville and 2 more locationsSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateStarted: February 23, 2026
- Recruitment status
- Recruiting
- Enrollment listed in the registry
- 100
- Sponsor
- University of North Carolina, Chapel Hill
- Sponsor type
- University
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- United States
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT06943404
- Official title
Show the full official title
Prevention/Reduction of ASRs and PTSD to Sustain Civilian Performance With a Sublingual Formulation of Dexmedetomidine (BXCL501)
Recruitment & locations
Currently recruitingA study may be recruiting, but some locations may no longer be accepting participants. Confirm availability with the research team.
Jacksonville · St Louis · Charlottesville
Questions about this study
Who is behind this study?
The study sponsor is University of North Carolina, Chapel Hill, a university.
Does this study involve medication?
Yes. The study involves medication, including BXCL501 (dexmedetomidine HCl) and Placebo.
Who can participate?
Listed age limits: 18 years to 65 years.
Is this study still recruiting?
The registry lists this study as recruiting.
